BTL-TML001

Drug Profile

BTL-TML001

Alternative Names: BTL TML001; BTL-TML-HSV

Latest Information Update: 25 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Beech Tree Labs
  • Class Antivirals; Small molecules
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Herpes labialis
  • Phase I/II Herpes simplex virus infections
  • No development reported Influenza virus infections

Most Recent Events

  • 25 Sep 2015 Combined efficacy data from two phase II trials in Herpes simplex virus infections released by Beech Tree Labs
  • 16 Sep 2015 No recent reports of development identified - Phase-I/II for Influenza virus infections in USA (unspecified route)
  • 01 Feb 2015 Beech Tree Labs completes a phase II trial in Herpes labialis (Recurrent) in USA (sublingual) (NCT01902303)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top